AUB ScholarWorks

Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search AUB ScholarWorks


Browse

My Account